PRESS RELEASE

Creat Group Corporation announces decision to make all-cash takeover offer to all Biotest shareholders - Biotest Board of Management and Supervisory Board support the offer

Munich, 7 April 2017 - Blitz 17-623 AG (in future: Tiancheng (Germany) Pharmaceutical Holdings AG), a company indirectly controlled by Creat Group Corporation ("Creat"), a leading Chinese investment group, today announces its decision to make a tender offer for all shares of Germany-listed Biotest AG ("Biotest") by way of a cash offer.

Creat intends to offer EUR 28.50 per ordinary share and EUR 19.00 per preference share in Biotest.

Creat is a long-term, strategic investor with significant expertise and a proven track record of investing and supporting growth in the global plasma industry evidenced by its investment in China's largest listed blood products company Shanghai RAAS as well as the 2016 acquisition of UK-based plasma supplier and manufacturer of plasma-derived protein therapeutics Bio Products Laboratory.

Biotest is a leading plasma company that provides plasma-derived protein therapeutics and biological plasma products. As a strategic partner, Creat will support Biotest's long-term strategy, in particular the expansion of the production facility in Dreieich, Germany. Creat appreciates the quality and dedication of Biotest's workforce in Germany and has no intention to conduct reductions or change the employment conditions.

Creat has the financial strength to support Biotest in funding the substantial investments in products and facilities required over the coming years to implement Biotest's recently adopted "Biotest Next Level" (BNL) strategy. As a strong player in Europe and the Middle East, Biotest greatly complements Creat's global portfolio and can benefit from resources especially in the fields of research and product development.

Xu Wu, CEO of Creat, says: "We intend to develop Biotest in line with the current management business plan to help unlock the company's full potential. Maintaining and building upon Biotest's strong talent base, its headquarters and corporate identity, we will support the required investments in products, R&D and BNL. Our support and investment will help create additional jobs in Germany and further increase the supply of life-saving products to patients. We look forward to working with the team at Biotest, for which we have the highest respect, on these ambitious plans."

Dr. Bernhard Ehmer, Chairman of Biotest's Board of Management, says: "We welcome the offer by Creat and see significant potential that Creat helps to strengthen our BNL strategy, allowing for additional investments in our business. This transaction would deliver immediate value for stakeholders and long term value for the company. Creat's commitments on a number of key issues are vital for Biotest and demonstrate the value that Creat places in our employees and our market position around the world."

OGEL GmbH comments: "As majority shareholder of Biotest, it is crucial that we do what is best for the company and its development. We have significantly supported Biotest since its foundation, and we continue to see great potential for the company in this sector. We are convinced that Creat is a competent partner for Biotest that will support the company in the implementation of BNL and ensure its long-term success."

OGEL GmbH irrevocably committed to tender its 50.6 per cent of Biotest's ordinary shares.

BofA Merrill Lynch is acting as financial advisor to Creat, Kirkland & Ellis International LLP is providing legal advice.

About Creat Group Corporation

Creat Group Corporation (www.creatgroup.com) is a leading Chinese investment group founded in 1992 that has significant expertise in the plasma industry. It invests in healthcare and pharmaceuticals, manufacturing, energy, finance, and natural resources. The company is based in Beijing, China, with other offices in Hong Kong and Shanghai. Through its investment in China's largest listed blood products company Shanghai RAAS as well as the 2016 acquisition of UK-based plasma supplier and manufacturer of plasma-derived protein therapeutics Bio Products Laboratory, Creat is a significant investor in the global plasma market.

Media contact

Knut Engelmann
CNC - Communications & Network Consulting AG
T +49 69 506 037 570